Fibrate therapy: An update

Cardiology in Review

Volumn 16, Issue 3, 2008, Pages 129-141

  Remick, Joshua ^a   Weintraub, Howard ^a   Setton, Robert ^a   Offenbacher, Joseph ^a   Fisher, Edward ^a   Schwartzbard, Arthur ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Fibrates; Metabolic syndrome; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOFIBRA; MEVINOLIN; MURAGLITAZAR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; TRIGLIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANGIOGRAPHY; ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BACKACHE; BACTERIAL INFECTION; BLOOD TOXICITY; CHOLANGITIS; CHOLECYSTITIS; CHOLELITHIASIS; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOCRIT; HUMAN; HYPESTHESIA; INSOMNIA; KIDNEY DYSFUNCTION; LACTATION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG EMBOLISM; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; MYOGLOBINURIA; MYOSITIS; PANCREATITIS; PARESTHESIA; POLYARTHRITIS; PREGNANCY; PRIMARY PREVENTION; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; TASTE DISORDER; VIRUS INFECTION;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; METABOLIC SYNDROME X; PPAR ALPHA;

EID: 42249113454     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31816b43d3     Document Type: Review

References (96)

1. Auboef D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of the peroxisome proliferators actived receptors and of LXR α mRNAs in human: effect of obesity and NIDDM in adipose tissue. Diabetes. 1997;46:319-1327.
2. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferators activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302:93-109.
3. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
4. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol. 1998;81:912-917.
5. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
6. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
7. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
8. Caslake M, Packard C, Gaw E, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702-711.
9. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563.
10. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6:209-214.
11. Krauss RM, Williams PT, Brensike J, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet. 1987;2:62-66.
12. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697-704.
13. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
14. Ruotolo G, Ericsson C-G, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoprotein and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
15. Syvanne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation. 1998;98:1993-1999.
16. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-278.
17. Grotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
18. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
19. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78:656-660.
20. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396-401.
21. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
22. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007;193:428-437.
23. Ericsson C-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
24. Ericsson C-G, Nilsson J, Grip L, et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol. 1997;80:1125-1129.
25. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-2143.
26. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
27. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 2001;357:905-910.
28. Chironi G, Simon A, Gariepy J, et al. Differential associations of statin and fibrate treatment with carotid arterial remodeling. Am Heart J. 2005;18:1476-1481.
29. Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem. 2006;52:2036-2042.
30. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
31. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
32. Vakkilaninen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733-1737.
33. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
34. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95-104.
35. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069-1118.
36. Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992;340:1405-1406.
37. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
38. Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
39. Tenkanen L, Pietila K, Manninen V, et al. The triglyceride issue revisited: findings from the Helsinki Heart Study. Arch Intern Med. 1994;154:2714-2720.
40. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779-1785.
41. Tenkanen L, Manttari M, Kovanen PT, et al. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-748.
42. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
43. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591.
44. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
45. Yusuf S, Hawken S, Ôunpuu S, et al. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
46. Barter PJ, Rye K-A. Cardioprotective properties of fibrates. Which fibrate, which patients, what mechanism? Circulation. 2006;113:1553-1555.
47. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.
48. Robins SJ, Rubins HB, Faas FH, et al. Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26:1513-1517.
49. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21-27.
50. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154-1160.
51. Tenenbaum A, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronoary artery disease by bezafibrate. Arch Intern Med. 2006;166:737-741.
52. Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26:2032-2038.
53. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
54. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
55. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomized controlled trial. Br Med J. 2002;325:1139-1143.
56. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006;17:431-439.
57. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
58. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366:1849-1861.
59. Bonora E, Forminitini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25:1135-1141.
60. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987;83(Suppl 5B):26-36.
61. Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993-1999.
62. Meade TW. Design and intermediate results of the lower extremity arterial disease event reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med. 2001;2:195-204.
63. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR- agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. JAMA. 2007;297:1362-1373.
64. Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46:347-351.
65. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
66. Opie LH. Metabolic syndrome. Circulation. 2007;115:32-35.
67. Pierce R, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-75.
68. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13-20.
69. Ellen RL, McPHerson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998;81:60B-65B.
70. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol. 1994;74:499-500.
71. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999;138:151-155.
72. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol. 1999;22:25-28.
73. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042-1051.
74. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2002;13:415-420.
75. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280-1287.
76. Physician's Desk Reference. 61st ed. Montvale, NJ: Thomson Healthcare Inc.; 2007:1219.
77. The PDR Pocket Guide to Prescription Drugs. 7th ed. New York, NY: Pocket Books, A Division of Simon and Scheuster, Inc.; 2005:774.
78. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227-239.
79. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729-741.
80. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005;26:897-905.
81. McKenney JM, Farnier M, Lo K-W, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006;47:1584-1587.
82. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
83. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
84. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177-1184.
85. Spencer GA, Wirebaugh S, Whitney EJ. Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol. 1996;36:696-700.
86. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
87. Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38:562-568.
88. Kottke TE, Chaffin J, Freeman G. Omega-3 fatty acids. The Institute for Medical Education Bulletin 2006; Vol. VII-No. 4.
89. 13th Conference on Retroviruses and Opportunistic infections. February 5-8, 2006. Available at: http://www.natap.org/2006/CROI/CROI_52.htm. Accessed January 20, 2008.
90. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586.
91. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. July 30, 2007. p. 108. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/ 2007-4308b1-02-fda-backgrounder.pdf. Accessed January 21, 2008.
92. Normen L, Frohlich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care. 2004;27:2241-2242.
93. Senba H, Kawano M, Kawakami M. Severe decrease in serum HDL-Cholesterol during combination therapy of bezafibrate and pioglitazone. J Atheroscler Thromb. 2006;13:263-264.
94. Ebcioglu Z, Morgan J, Carey C, et al. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinediones. Ann Intern Med. 2003;139:W80.
95. Sarker A, Semple RK, Dinneen AF, et al. Severe hypo-α- lipoproteinemia during treatment with rosiglitazone. Diabetes Care. 2005;27:2577-2580.
96. Brunzell JD. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-1017.